Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.

doi:10.1073/pnas.1905384117

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.

Proceedings of the National Academy of Sciences of the United States of America - 28 Jan 2020

Hsu En-Chi, Rice Meghan A, Bermudez Abel, Marques Fernando Jose Garcia, Aslan Merve, Liu Shiqin, Ghoochani Ali, Zhang Chiyuan Amy, Chen Yun-Sheng, Zlitni Aimen, Kumar Sahil, Nolley Rosalie, Habte Frezghi, Shen Michelle, Koul Kashyap, Peehl Donna M, Zoubeidi Amina, Gambhir Sanjiv S, Kunder Christian A, Pitteri Sharon J, Brooks James D, Stoyanova Tanya

Abstract excerpt

Resistance to androgen deprivation therapy, or castration-resistant prostate cancer (CRPC), is often accompanied by metastasis and is currently the ultimate cause of prostate cancer-associated deaths in men. Recently, secondary hormonal therapies have led to an increase of neuroendocrine prostate cancer (NEPC), a highly aggressive variant of CRPC. Here, we identify that high levels of cell surface receptor Trop2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Carcinoma, Neuroendocrine

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Poly (ADP-Ribose) Polymerase-1

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prostatic Neoplasms, Castration-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 31932422
DOI: 10.1073/pnas.1905384117
PMCID: PMC6994991

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.PMID 31932422Read ↗

Molecular model for neuroendocrine prostate cancer progressionSemantic proximity Read ↗

Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance.Semantic proximity Read ↗

Distinct prostate cancer neuroendocrine subtypes predict prognosis and guide personalized prostate-specific membrane antigen-targeted therapySemantic proximity Read ↗

ONECUT2 is a driver of neuroendocrine prostate cancerSemantic proximity Read ↗

BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2Semantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.Semantic proximity Read ↗

The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerSemantic proximity Read ↗

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancerSemantic proximity Read ↗

Assessment of Cell Surface Targets in Metastatic Prostate Cancer: Expression Landscape and Molecular CorrelatesSemantic proximity Read ↗

Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4Semantic proximity Read ↗

The transcriptional landscape of metastatic hormone-naïve prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.